174 related articles for article (PubMed ID: 18565233)
1. Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
Tenenbaum A; Boyko V; Fisman EZ; Goldenberg I; Adler Y; Feinberg MS; Motro M; Tanne D; Shemesh J; Schwammenthal E; Behar S
Cardiovasc Diabetol; 2008 Jun; 7():18. PubMed ID: 18565233
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment.
Node K; Inoue T; Boyko V; Goldberg I; Fisman EZ; Adler Y; Schwammenthal E; Matas Z; Behar S; Tenenbaum A
Cardiovasc Diabetol; 2009 Jan; 8():5. PubMed ID: 19173749
[TBL] [Abstract][Full Text] [Related]
3. Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial.
Arbel Y; Klempfner R; Erez A; Goldenberg I; Benzekry S; Shlomo N; Fisman EZ; Tenenbaum A;
Cardiovasc Diabetol; 2016 Jan; 15():11. PubMed ID: 26794137
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
Tenenbaum A; Motro M; Fisman EZ; Schwammenthal E; Adler Y; Goldenberg I; Leor J; Boyko V; Mandelzweig L; Behar S
Circulation; 2004 May; 109(18):2197-202. PubMed ID: 15123532
[TBL] [Abstract][Full Text] [Related]
5. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Tenenbaum A; Motro M; Fisman EZ
Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
[TBL] [Abstract][Full Text] [Related]
6. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry.
Klempfner R; Erez A; Sagit BZ; Goldenberg I; Fisman E; Kopel E; Shlomo N; Israel A; Tenenbaum A
Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):100-8. PubMed ID: 26957517
[TBL] [Abstract][Full Text] [Related]
7. Association of Bezafibrate Treatment With Reduced Risk of Cancer in Patients With Coronary Artery Disease.
Iakobishvili Z; Hasin T; Klempfner R; Shlomo N; Goldenberg I; Brenner R; Kornowski R; Gerber Y
Mayo Clin Proc; 2019 Jul; 94(7):1171-1179. PubMed ID: 31272567
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.
Tenenbaum A; Fisman EZ; Boyko V; Benderly M; Tanne D; Haim M; Matas Z; Motro M; Behar S
Arch Intern Med; 2006 Apr; 166(7):737-41. PubMed ID: 16606809
[TBL] [Abstract][Full Text] [Related]
9. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands.
Kohno H; Suzuki R; Sugie S; Tanaka T
BMC Cancer; 2005 May; 5():46. PubMed ID: 15892897
[TBL] [Abstract][Full Text] [Related]
10. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
[TBL] [Abstract][Full Text] [Related]
11. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
Ericsson CG; Hamsten A; Nilsson J; Grip L; Svane B; de Faire U
Lancet; 1996 Mar; 347(9005):849-53. PubMed ID: 8622389
[TBL] [Abstract][Full Text] [Related]
12. [BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].
Yoshino G; Hirano T; Kazumi T
Nihon Rinsho; 2001 Mar; 59 Suppl 3():433-5. PubMed ID: 11347109
[No Abstract] [Full Text] [Related]
13. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Fruchart JC; Duriez P
Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes.
Tenenbaum H; Behar S; Boyko V; Adler Y; Fisman EZ; Tanne D; Lapidot M; Schwammenthal E; Feinberg M; Matas Z; Motro M; Tenenbaum A
Atherosclerosis; 2007 Sep; 194(1):265-71. PubMed ID: 16970952
[TBL] [Abstract][Full Text] [Related]
15. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
Brodov Y; Behar S; Boyko V; Chouraqui P
Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615
[TBL] [Abstract][Full Text] [Related]
16. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.
de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():257-63. PubMed ID: 9211018
[TBL] [Abstract][Full Text] [Related]
17. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level.
Hiuge A; Tenenbaum A; Maeda N; Benderly M; Kumada M; Fisman EZ; Tanne D; Matas Z; Hibuse T; Fujita K; Nishizawa H; Adler Y; Motro M; Kihara S; Shimomura I; Behar S; Funahashi T
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):635-41. PubMed ID: 17194889
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
Elkeles RS; Diamond JR; Poulter C; Dhanjil S; Nicolaides AN; Mahmood S; Richmond W; Mather H; Sharp P; Feher MD
Diabetes Care; 1998 Apr; 21(4):641-8. PubMed ID: 9571357
[TBL] [Abstract][Full Text] [Related]
19. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
Corpechot C; Chazouillères O; Rousseau A; Le Gruyer A; Habersetzer F; Mathurin P; Goria O; Potier P; Minello A; Silvain C; Abergel A; Debette-Gratien M; Larrey D; Roux O; Bronowicki JP; Boursier J; de Ledinghen V; Heurgue-Berlot A; Nguyen-Khac E; Zoulim F; Ollivier-Hourmand I; Zarski JP; Nkontchou G; Lemoinne S; Humbert L; Rainteau D; Lefèvre G; de Chaisemartin L; Chollet-Martin S; Gaouar F; Admane FH; Simon T; Poupon R
N Engl J Med; 2018 Jun; 378(23):2171-2181. PubMed ID: 29874528
[TBL] [Abstract][Full Text] [Related]
20. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.
Ruotolo G; Båvenholm P; Brismar K; Eféndic S; Ericsson CG; de Faire U; Nilsson J; Hamsten A
J Am Coll Cardiol; 2000 Mar; 35(3):647-54. PubMed ID: 10716467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
